Aptevo Therapeutics Inc. APVO jumped 46.10% to $2.06 during after-hours trading on Wednesday following breakthrough clinical results demonstrating its drug’s potential to redefine frontline AML treatment.Check out the current price of APVO stock here.Clinical Trial Delivers Perfect Remission RateThe biotech company from Seattle reported that all patients in Cohort 3 of its Phase 1b/2 RAINIER trial went into complete remission. The trial is testing a treatment called mipletamig, combined with venetoclax and ...